Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants

Benzinga_recent_news

Nov 12, 2025

One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582339706"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582339706\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582339706?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/Hims--Hers.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-11-12 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582339706","market":"us","top_or_hot":-1,"title":"Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants","media":"Benzinga_recent_news","content":"<div>\n<p>One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong ...</p>\n\n<a href=\"https://www.benzinga.com/markets/options/25/11/48791116/hims-stock-earnings-downturn-compelling-contrarian-trade\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptions Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-12 04:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/options/25/11/48791116/hims-stock-earnings-downturn-compelling-contrarian-trade><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong ...</p>\n\n<a href=\"https://www.benzinga.com/markets/options/25/11/48791116/hims-stock-earnings-downturn-compelling-contrarian-trade\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.benzinga.com/markets/options/25/11/48791116/hims-stock-earnings-downturn-compelling-contrarian-trade","article_id":"2582339706","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/Hims--Hers.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/options/25/11/48791116/hims-stock-earnings-downturn-compelling-contrarian-trade","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582339706","pubTimestamp":1762894500,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Although Hims & Hers Health has tanked in the past month, the quantitative profile suggests a contrarian trade is brewing for HIMS stock.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc."},"translate_title":"期权角：Hims&Hers Health的低迷为量化分析师提供了令人信服的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong demand for weight-loss treatments. However, it's also a speculative investment, with the wellness platform facing a crowded digital health industry along with a steep valuation. Still, the quantitative picture for HIMS stock appears intriguing.\nTo be upfront, the idea of Hims & Hers Health entered my inbox earlier this morning as a spam-like ticker recommendation. Initially, my instinct was to ignore it like every other piece of junk mail that I receive on the daily — and for good reason. While HIMS stock is up more than 68% on a year-to-date basis, it's been down roughly 26% in the trailing month.\nStill, there's a possibility that the selloff — just from a fundamental perspective — may be overdone. Sure, the company posted earnings of 6 cents per share, missing the consensus target of 9 cents. However, revenue landed at $598.97 million, jumping well above analysts' expectations, calling for $580.24 million.\nJust as importantly, the telehealth specialist's subscriber count grew to almost 2.5 million, representing a lift of 21% against the year-ago quarter. Skeptics might argue that even with these metrics, the valuation is rich, with investors paying 64-times forward earnings and almost five-times trailing-year sales.\nHowever, valuation ratios are not universal truth claims and they don't correlate with investment returns. Otherwise, if they did, people who divide numbers would be the richest people on earth. As it turns out, there's a better way to identify and extract asymmetrical pricing opportunities.\nIn the movie \"Forrest Gump,\" we were told that life is like a box of chocolates. However, this metaphor works for long-term uncertainty as we really don't know what's going to happen, say, five years from now. In the market, that's an eternity. But in the short term, life is like a distribution of probabilistic outcomes.\nGranted, that would be a very jarring line to put into the film. Yet this is how life works. When the sky turns cloudy, you wear warmer clothes — maybe take an umbrella. If you notice that it's four in the afternoon on a Tuesday, you may decide to take a less-crowded route home.\nWe operate daily in probabilistic frameworks. Yet for some astoundingly wild reason, we don't apply the same logic to options trading. It's time to change that.\nBorrowing from the foundational work of Russian mathematicians Andrey Kolmogorov and Andrey Markov, we can define price behavior as a discretized and measurable probability space with real  outcomes and distributional probabilities. Further, by measuring the variance between expected and contextually realistic outcomes, we can potentially identify an informational arbitrage that's unknown to traders who rely exclusively on fundamental and technical analysis.\nUsing Russian axioms, the forward 10-week median returns of HIMS stock can be arranged as a distributional curve, with outcomes ranging between $39.92 and $40.88 (assuming an anchor price of $40.42). Further, price clustering would be expected to occur predominantly at $40.39.\nThe above assessment represents data aggregated since HIMS' public market debut. However, HIMS is currently not in a homeostatic or baseline state but rather in a distributive 4-6-D formation; that is, in the trailing 10 weeks, HIMS stock printed four up weeks and six down weeks, with an overall downward slope.\nUnder this specific condition, forward 10-week outcomes would be expected to range between $37.50 and $52.70. So, while the possibility of downside is enhanced, the reward tail jumps out much further, thus incentivizing a bullish posture.\nMost importantly, price clustering would likely be predominant at around $42.70. That means in terms of density dynamics, there's a 5.72% delta between the outcome that most people are expecting versus the contextually realistic outcome that's forecasted by the 4-6-D sequence.\nBased on the numbers above, the 40/43 bull call spread expiring Dec. 19 may be the most intriguing idea. This transaction involves buying the $40 call and simultaneously selling the $43 call, for a net debit paid of $140 (the most that can be lost).\nIf HIMS stock rises through the second-leg strike ($43) at expiration, the maximum reward is $160, a payout of over 114%. Breakeven lands at $41.40, which, if the above assessment holds true, is a very comfortable threshold.\nFor those who really want to go for it, there is a case to be made for the 42/45 bull spread also expiring Dec. 19. In this case, HIMS stock will need to rise through the $45 strike at expiration. However, secondary clustering data shows that this is very much a possibility.\nIt's super-risky and so, those who are anxious may prefer the more probabilistically tenable 40/43 spread. Nevertheless, the 42/45 spread makes a powerful case because of the 152% max payout.\nThe opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.\nRead Next:\nPhoto: Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}